Iatrogenic Esophageal Perforation After ERCP Early Recognition and Outcome Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development

Dr Karuna Sharma [1*], Dr Sarveshwar [2]
[1-2] Resident, General Surgery, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India

* Corresponding Author: **Dr Karuna Sharma**

Article Info

ISSN (online): 2582-8940
Volume: 07
Issue: 01
Received: 20-11-2025
Accepted: 22-12-2025
Published: 24-01-2026
Page No: 107-118

Abstract

Background: Iatrogenic esophageal perforation represents a catastrophic complication of endoscopic retrograde cholangiopancreatography with mortality rates reaching 10-25%, yet therapeutic options remain limited to surgical intervention and supportive care. The absence of targeted pharmacological therapies for tissue repair, infection prevention, and inflammation modulation in gastrointestinal perforations reflects broader challenges in pharmaceutical development, including prolonged discovery timelines averaging 12-15 years, high clinical attrition rates exceeding 90%, and inadequate translation of preclinical findings to clinical efficacy. Current drug discovery paradigms face substantial obstacles in identifying and validating therapeutic targets for acute surgical complications and developing agents that promote accelerated tissue healing while preventing septic complications.

Aim: This article examines innovative pharmaceutical development strategies applicable to acute gastrointestinal injuries, linking clinical management of iatrogenic esophageal perforation with contemporary drug discovery approaches including high-throughput screening, computational target identification, and translational research frameworks.

Discussion: Modern drug development increasingly employs high-throughput screening platforms evaluating millions of compounds against validated biological targets, structure-based drug design leveraging three-dimensional protein structures, and systems biology approaches identifying network-level therapeutic opportunities. Target identification through genomic and proteomic profiling, coupled with advanced preclinical models recapitulating human tissue injury and repair, enables more predictive assessment of clinical translation. Lead optimization employs multi-parameter approaches simultaneously enhancing potency, selectivity, and pharmaceutical properties.

Impact: Implementation of accelerated development strategies demonstrates substantial reductions in discovery timelines and improved clinical success rates, particularly for repurposed therapeutics and precision medicine applications targeting specific patient populations or injury mechanisms.

Outlook: Future advancement requires integration of artificial intelligence-driven compound prediction, patient-specific biomarker development, organoid-based disease modeling, and adaptive clinical trial designs to optimize therapeutic development for acute surgical complications and critical care applications.

DOI: https://doi.org/10.54660/IJMBHR.2026.7.1.107-118

Keywords: Drug Discovery, Pharmaceutical Development, Translational Research, High-Throughput Screening, Lead Optimization, Precision Medicine

Introduction

Iatrogenic esophageal perforation constitutes one of the most serious complications of endoscopic procedures, particularly endoscopic retrograde cholangiopancreatography, with incidence rates reported between 0.1% and 0.5% but associated with profound morbidity and mortality. The esophagus lacks a serosal layer, making perforations particularly prone to rapid mediastinal contamination, systemic sepsis, and multi-organ failure. Traditional management relies primarily on early recognition, broad-spectrum antimicrobial therapy, nutritional support, and surgical or endoscopic closure, yet outcomes remain suboptimal with mortality rates ranging from 10% to 25% even with prompt intervention.

The absence of targeted pharmacological agents that can accelerate tissue repair, modulate inflammatory responses, or prevent infectious complications represents a significant gap in therapeutic armamentarium for acute gastrointestinal injuries.

The pathophysiology of esophageal perforation involves complex biological processes including immediate tissue disruption, hemorrhage, contamination with oral and gastric flora, intense local and systemic inflammatory responses, impaired tissue healing in contaminated environments, and potential progression to mediastinitis, empyema, and septic shock. Effective pharmacological interventions would ideally address multiple pathophysiological targets including promotion of epithelial regeneration, enhancement of microvascular perfusion to injured tissues, modulation of excessive inflammatory responses that impair healing, prevention or treatment of polymicrobial infections in compromised tissues, and reduction of fibrotic responses that may lead to stricture formation. Despite clear clinical need, no specific therapeutic agents have been developed and approved for these indications, reflecting broader challenges in pharmaceutical development for acute surgical complications and critical care scenarios.

The pharmaceutical industry faces escalating challenges in drug discovery and development, with research and development costs exceeding 2.6 billion dollars per approved medication and average timelines from initial discovery to market authorization spanning 12-15 years. Clinical trial failure rates remain alarmingly high, with approximately 90% of compounds entering clinical testing ultimately failing to achieve regulatory approval. These failures predominantly occur in phase II and III trials, after substantial investment in preclinical development and early clinical studies, often due to inadequate efficacy in human disease despite promising preclinical results or emergence of unacceptable toxicities not predicted by animal models. For acute conditions including iatrogenic injuries, additional development challenges include difficulty recruiting adequate patient populations for clinical trials, ethical complexities of randomizing critically ill patients, rapid disease progression requiring immediate intervention, and heterogeneity of injury severity and patient comorbidities complicating outcome assessment.

Contemporary drug discovery has undergone revolutionary transformation through integration of high-throughput technologies, computational approaches, and systematic translational research methodologies. Target identification increasingly leverages genomic, transcriptomic, and proteomic data to identify disease-relevant molecular pathways amenable to therapeutic intervention. High-throughput screening platforms enable evaluation of millions of chemical compounds against validated targets, dramatically accelerating hit identification compared with traditional empirical approaches. Structure-based drug design utilizes high-resolution three-dimensional structures of therapeutic targets to rationally design optimized compounds with enhanced potency and selectivity. Translational research frameworks emphasize mechanistic understanding of disease pathophysiology, development of predictive biomarkers, and selection of preclinical models that accurately recapitulate human disease features, improving likelihood of clinical translation.

This manuscript examines contemporary pharmaceutical development strategies and their potential application to acute gastrointestinal injuries, using iatrogenic esophageal perforation as an illustrative clinical scenario. We explore how modern approaches including high-throughput screening, computational target identification, advanced preclinical modeling, and precision medicine frameworks could accelerate development of therapeutics for surgical complications and critical care applications. Understanding these innovative strategies provides essential context for clinicians, researchers, and pharmaceutical scientists engaged in translating basic discoveries into clinical therapeutics for unmet medical needs in acute care medicine and surgical specialties.

Modern Approaches in Target Identification and Validation

Target identification represents the critical foundational step in rational drug discovery, requiring comprehensive understanding of disease mechanisms and identification of specific molecular entities whose modulation will produce therapeutic benefit. For iatrogenic esophageal perforation and tissue injury repair, relevant therapeutic targets span multiple biological systems including growth factors and their receptors regulating epithelial proliferation and migration, extracellular matrix proteins and remodeling enzymes governing tissue architecture, inflammatory mediators including cytokines and chemokines orchestrating immune responses, microvascular endothelial factors controlling perfusion and angiogenesis, antimicrobial peptides and immune effectors preventing infection, and cellular stress response pathways influencing cell survival in injured tissues.

Contemporary target identification strategies employ unbiased high-throughput approaches to systematically survey disease-relevant biological changes. Genome-wide association studies identify genetic variants associated with wound healing capacity, infection susceptibility, or fibrotic responses, revealing previously unsuspected therapeutic targets. Transcriptomic profiling using RNA sequencing technologies characterizes gene expression changes in injured versus healthy esophageal tissues, identifying dysregulated pathways amenable to pharmacological intervention. Single-cell RNA sequencing provides unprecedented resolution of cellular heterogeneity in injury sites, revealing cell type-specific responses and potential therapeutic targets. Proteomic approaches including mass spectrometry-based protein identification enable comprehensive characterization of protein expression, post-translational modifications, and protein-protein interactions in tissue repair processes.

Spatial transcriptomics and proteomics technologies enable mapping of molecular changes within intact tissue architecture, preserving critical spatial context often lost in traditional homogenized tissue analyses. These approaches reveal zone-specific responses in injured tissues, including epithelial proliferation at wound edges, inflammatory cell infiltration in deeper layers, and fibroblast activation in surrounding connective tissues. Understanding spatial organization of molecular responses enables identification of targets whose modulation will produce beneficial effects in specific tissue compartments while minimizing off-target effects in uninvolved regions.

Target validation constitutes perhaps the most critical phase of drug discovery, requiring definitive demonstration that modulating a specific molecular target will produce desired therapeutic effects without unacceptable toxicity. Inadequate

target validation represents a leading cause of clinical trial failures, as many promising preclinical targets fail to demonstrate clinical efficacy due to compensatory mechanisms, species differences in target biology, or fundamental errors in disease mechanism understanding. Rigorous validation approaches employ multiple complementary methodologies to build confidence in therapeutic potential before committing substantial resources to compound screening and optimization.

Genetic validation approaches utilize gene knockout, knockdown, or overexpression to assess phenotypic consequences of target modulation in cell culture and animal models. CRISPR-Cas9 genome editing technologies enable precise, efficient genetic modifications in diverse experimental systems, facilitating definitive assessment of target relevance to disease processes. Conditional knockout approaches allow temporal and tissue-specific gene ablation, addressing concerns that constitutive knockout may produce developmental compensations masking adult therapeutic potential. Inducible systems enable acute target modulation more closely mimicking pharmacological intervention timelines.

Chemical genetics approaches employ selective small molecule tool compounds to acutely modulate target function, providing validation more representative of intended therapeutic intervention compared with genetic approaches producing permanent target ablation. Chemical validation reveals whether therapeutic windows exist between efficacy and toxicity, identifies potential mechanism-based adverse effects, and informs optimal dosing strategies. For tissue repair applications, chemical validation in wound healing models can demonstrate whether target modulation accelerates closure kinetics, improves healed tissue strength, or reduces infectious complications.

Biomarker development represents an integral component of target validation, enabling objective assessment of target engagement and pathway modulation in preclinical and clinical studies. Pharmacodynamic biomarkers demonstrate dose-dependent changes with target modulation, correlate with therapeutic effects, and are measurable in accessible biological specimens. For esophageal injury, relevant biomarkers might include circulating growth factors, inflammatory cytokines, tissue repair proteins, or cellular markers of proliferation and apoptosis measurable in blood or tissue biopsies. Validated biomarkers facilitate dose-finding studies, enable early clinical proof-of-concept assessment, and support patient selection for precision medicine approaches.

Systems biology methodologies integrate multi-omics data including genomics, transcriptomics, proteomics, and metabolomics to construct comprehensive models of tissue injury and repair processes. Network analysis identifies highly connected hub proteins and critical pathway nodes representing attractive therapeutic targets. These approaches recognize that effective therapeutics often modulate multiple targets within biological networks rather than acting exclusively on single molecules, providing rationale for polypharmacology and combination therapy development. For complex processes like tissue repair, network-level interventions may prove more effective than single-target approaches.

High-Throughput Screening and Lead Optimization

High-throughput screening represents a transformative technology enabling simultaneous evaluation of hundreds of thousands to millions of chemical compounds for biological activity against validated therapeutic targets. Contemporary screening platforms integrate advanced robotics, automated liquid handling systems, miniaturized assay formats typically in 384-well or 1536-well microplates, and sophisticated detection technologies including fluorescence, luminescence, and high-content imaging. These integrated systems can evaluate complete corporate compound collections or large commercial chemical libraries within several weeks, dramatically accelerating hit identification compared with traditional low-throughput approaches requiring months or years for comparable screening campaigns.

Assay development for high-throughput screening requires substantial optimization to ensure robust, reproducible performance in miniaturized formats under automated conditions. Ideal screening assays demonstrate excellent signal-to-noise ratios exceeding ten-fold, minimal variability with Z-prime factors above 0.5, and stability over extended screening campaigns spanning multiple days. Biochemical assays directly measure target binding affinity, enzymatic activity, or protein-protein interactions in cell-free systems, offering simplicity and reproducibility but potentially missing cellular context effects. Cell-based assays evaluate compound effects in living cells, providing more physiologically relevant assessment of activity but introducing complexity from cellular uptake, metabolism, and off-target effects.

Phenotypic screening approaches assess compound effects on complex cellular behaviors including migration, proliferation, differentiation, or morphological changes without requiring prior knowledge of specific molecular targets. These unbiased approaches can identify compounds with optimal cellular activity profiles and potentially reveal novel mechanisms of action. For tissue repair applications, phenotypic screens might evaluate keratinocyte migration in scratch wound assays, fibroblast proliferation and collagen deposition, endothelial tube formation modeling angiogenesis, or three-dimensional organoid growth and differentiation. Compounds demonstrating favorable phenotypic effects undergo subsequent target deconvolution to identify molecular mechanisms enabling rational optimization.

Hit-to-lead optimization transforms initial screening hits, which typically demonstrate modest potency in micromolar ranges and suboptimal pharmaceutical properties, into lead compounds suitable for further development. This process employs medicinal chemistry expertise combined with systematic structure-activity relationship studies exploring how structural modifications affect biological activity. Computational chemistry tools including molecular docking simulations, pharmacophore modeling, and quantitative structure-activity relationship analyses guide optimization efforts by predicting how proposed structural changes will influence target binding and overall activity. Parallel synthesis approaches enable rapid generation of focused compound libraries systematically exploring structural variations around promising hits.

Lead optimization represents the most resource-intensive phase of preclinical drug discovery, requiring iterative cycles of compound design and synthesis, biological testing across multiple assays, and assessment of pharmaceutical properties. Multi-parameter optimization addresses simultaneous improvement of numerous attributes including potency against primary target, selectivity over related proteins to minimize off-target effects, metabolic stability ensuring adequate drug exposure duration, membrane permeability enabling cellular uptake and tissue distribution, aqueous solubility facilitating formulation development, and absence of reactive functional groups that may cause toxicity. Balancing these often-competing requirements demands sophisticated medicinal chemistry strategies and willingness to sacrifice activity in some parameters to achieve overall optimal profiles.

Physicochemical property optimization follows established guidelines including Lipinski's Rule of Five, which defines ranges for molecular weight, lipophilicity, hydrogen bond donors and acceptors associated with favorable oral bioavailability. For tissue repair applications requiring direct delivery to injury sites, alternative property profiles emphasizing aqueous solubility and minimizing systemic absorption may prove optimal. Structure-based design leverages high-resolution three-dimensional structures of therapeutic targets, typically obtained through X-ray crystallography or increasingly through cryo-electron microscopy, to rationally design compounds with optimal binding geometries and interactions. Co-crystal structures showing lead compounds bound within target binding sites provide invaluable insights guiding optimization toward improved potency and selectivity.

Fragment-based drug discovery offers complementary approaches to traditional high-throughput screening, employing libraries of small low-complexity molecular fragments rather than larger drug-like molecules. Fragment hits demonstrate weak binding affinities but high ligand efficiency, making efficient use of constituent atoms to achieve target engagement. These fragments serve as starting points for structure-guided elaboration into more potent leads. Fragment screening requires sensitive biophysical methods including nuclear magnetic resonance spectroscopy, surface plasmon resonance, or thermal shift assays to detect weak binding events, but can explore chemical space inaccessible to traditional screening approaches and often yields highly efficient leads amenable to optimization.

Preclinical and Translational Strategies

Preclinical development encompasses comprehensive characterization of drug candidates' pharmacological, toxicological, and pharmaceutical properties before first-in-human studies. Contemporary preclinical strategies emphasize early identification of potential liabilities through systematic profiling, enabling termination of problematic candidates before substantial investment while advancing only compounds with favorable overall profiles. Pharmacokinetic characterization in multiple species establishes absorption, distribution, metabolism, and excretion properties, enabling prediction of human pharmacokinetics and identification of appropriate clinical doses based on exposure-response relationships established in efficacy models.

In vitro absorption, distribution, metabolism, and excretion profiling employs standardized assays assessing metabolic stability in liver microsomes or hepatocytes, membrane permeability using Caco-2 cell monolayers or parallel artificial membrane permeability assays, plasma protein binding, cytochrome P450 enzyme inhibition and induction, and active transporter interactions. These studies identify potential drug-drug interaction liabilities, predict likely routes of elimination, and assess species differences in metabolism that may complicate toxicology interpretation or clinical translation. Compounds demonstrating poor pharmaceutical properties can be deprioritized, focusing resources on candidates with superior profiles more likely to succeed in clinical development.

Safety pharmacology studies assess drug effects on critical organ systems including cardiovascular, respiratory, and central nervous systems to identify potential adverse effects before clinical trials. Cardiovascular safety assessment includes *in vitro* evaluation of human ether-a-go-go-related gene potassium channel inhibition predicting QT interval prolongation risk, followed by *in vivo* electrocardiographic monitoring and blood pressure assessment in conscious animals. The comprehensive *in vitro* proarrhythmia assay employs human induced pluripotent stem cell-derived cardiomyocytes with computational modeling to predict proarrhythmic risk with improved sensitivity and specificity compared with traditional approaches. Early identification of safety concerns enables structural modification to eliminate liabilities or informed risk-benefit assessment in development planning.

Toxicology studies in rodent and non-rodent species establish safe starting doses for clinical trials, identify target organ toxicities requiring clinical monitoring, and characterize dose-limiting toxicities. Acute toxicity studies establish lethal doses and maximum tolerated doses informing dose-ranging for repeated-dose studies. Repeated-dose toxicity studies typically spanning 28 days to 6 months evaluate effects of chronic exposure, identifying cumulative toxicities not apparent with single doses. Genetic toxicology assays assess mutagenic potential through bacterial reverse mutation tests and chromosomal aberration studies, while carcinogenicity studies may be required for drugs intended for chronic administration. For acute applications like tissue repair agents, abbreviated toxicology programs may suffice given limited exposure duration.

Translational research frameworks emphasize bidirectional information flow between preclinical and clinical investigations, ensuring clinical relevance of preclinical models while enabling mechanistic understanding of clinical observations. Effective translation requires disease models accurately recapitulating key features of human pathophysiology and predicting clinical therapeutic responses. For esophageal perforation, relevant models might include surgical perforation in large animals allowing assessment of healing kinetics and infectious complications, ex vivo human esophageal tissue culture models evaluating epithelial repair mechanisms, and three-dimensional organoid systems derived from human esophageal stem cells recapitulating tissue architecture and regenerative capacity.

Animal models of tissue injury must balance practical considerations including cost, availability, surgical feasibility, and ethical acceptability with requirements for pathophysiological relevance and clinical predictivity. Large animal models including pigs offer anatomical and physiological similarity to humans but require substantial resources and specialized facilities. Rodent models provide

cost-effective, genetically tractable systems enabling mechanistic investigations but may not accurately predict human responses due to species differences in healing kinetics, immune responses, and infection susceptibility. Emerging alternatives including human tissue explants and organoid cultures provide human-relevant systems while reducing animal use, though they cannot fully recapitulate systemic responses relevant to sepsis and multi-organ effects.
Pharmacometric approaches including population pharmacokinetic-pharmacodynamic modeling integrate preclinical and clinical data to optimize dose selection and predict response variability. These quantitative frameworks characterize relationships between dose, exposure, target engagement, and therapeutic effects, enabling simulation of clinical trial outcomes under different dosing scenarios. Model-informed drug development strategies use these predictions to guide development decisions, identify optimal patient populations, and design efficient clinical trials. For tissue repair agents, pharmacometric models might predict healing kinetics based on drug exposure at injury sites, inflammatory marker dynamics, and patient-specific factors including age, nutritional status, and comorbidities.

Clinical Development Innovations

Clinical development encompasses progressive evaluation of therapeutic candidates in human subjects, from initial safety and pharmacokinetic studies through definitive efficacy trials supporting regulatory approval. Contemporary clinical development strategies emphasize adaptive designs enabling protocol modifications based on accumulating data, enrichment approaches selecting patient populations most likely to benefit, and innovative trial designs improving efficiency and reducing costs. First-in-human studies establish safety, tolerability, and pharmacokinetic profiles, identifying dose ranges for efficacy studies and characterizing dose-limiting toxicities. For tissue repair applications, first-in-human studies might employ ascending-dose designs in healthy volunteers or surgical patients with minor injuries before advancing to more severe clinical scenarios.
Phase II proof-of-concept studies provide initial efficacy signals guiding go/no-go decisions for costly phase III trials while characterizing dose-response relationships informing optimal dose selection. For iatrogenic esophageal perforation, phase II studies face substantial challenges including relatively low incidence limiting patient availability, severity of condition potentially precluding randomization to placebo, and heterogeneity in perforation size, location, and timing of diagnosis affecting baseline prognosis. Adaptive design approaches allow mid-trial modifications including sample size adjustment based on observed effect sizes, dose selection based on accumulating pharmacokinetic-pharmacodynamic data, and enrichment for biomarker-defined subpopulations demonstrating superior responses.
Seamless phase II/III designs integrate learning and confirmatory phases within single master protocols, potentially reducing timelines and costs by eliminating gaps between studies. Patients enrolled during learning phases may contribute to confirmatory analyses if randomized to doses selected for phase III, maximizing data utilization. Basket trial designs enable evaluation of single therapeutics across multiple disease subtypes sharing common molecular features, while umbrella designs assess multiple therapies within single disease populations, both improving efficiency particularly for precision medicine approaches targeting specific biomarker-defined patient subgroups.
For esophageal perforation and similar acute surgical complications, pragmatic trial designs embedded within routine clinical care may enhance feasibility and generalizability compared with traditional explanatory trials with restrictive inclusion criteria. Pragmatic designs employ broad eligibility criteria encompassing diverse patient populations encountered in clinical practice, compare interventions against usual care rather than placebo when ethically required, and assess outcomes meaningful to patients and clinicians including mortality, hospital length of stay, and quality of life rather than surrogate biomarkers. Electronic health record integration enables efficient patient identification, data collection, and outcome ascertainment while minimizing research burden on clinical teams and patients.
Bayesian adaptive randomization approaches continuously update randomization probabilities based on accumulating outcome data, assigning higher proportions of new patients to better-performing treatments. This response-adaptive strategy can improve trial efficiency and ethical acceptability by minimizing patient exposure to inferior treatments while maintaining statistical validity. Platform trials provide standing infrastructure enabling efficient evaluation of multiple therapies sequentially or simultaneously within common protocols, particularly valuable for rare conditions where traditional individual trials would require prohibitively long enrollment periods.
Real-world evidence generation using electronic health records, insurance claims databases, and patient registries complements traditional randomized controlled trials by providing effectiveness and safety data from broader, more diverse populations under routine clinical conditions. Observational studies cannot definitively establish causality but can identify treatment patterns, characterize real-world patient populations, detect rare adverse events requiring large exposure populations, and generate hypotheses for prospective evaluation. For tissue repair agents, real-world evidence might characterize utilization patterns, identify patient subgroups with differential outcomes, and detect safety signals requiring further investigation.

Technological and Computational Enhancements

Artificial intelligence and machine learning technologies are revolutionizing drug discovery through enhanced prediction of compound properties, automated experimental design, and integration of diverse data types into predictive models. Deep learning algorithms predict compound activity, toxicity, selectivity, and pharmaceutical properties from molecular structures with increasing accuracy, enabling virtual screening of chemical libraries containing millions to billions of theoretical compounds impossible to physically synthesize and test. These predictive models, trained on extensive datasets of experimentally measured properties, continuously improve as additional data accumulate, creating positive feedback loops enhancing prediction accuracy over time.
Generative artificial intelligence models design novel molecular structures optimized for specified property profiles, exploring chemical space beyond what medicinal chemists might conceive through traditional design approaches. These algorithms learn structural patterns associated with desired activities from training data, then

generate novel molecules predicted to demonstrate those activities while satisfying pharmaceutical property constraints. Reinforcement learning approaches optimize generated structures through iterative cycles of generation, property prediction, and structure refinement, converging toward molecules with optimal multi-parameter profiles. For tissue repair applications, generative models might design growth factor mimetics, anti-inflammatory agents, or antimicrobial peptides with enhanced potency, stability, and tissue penetration.

Natural language processing and text mining extract information from scientific literature, patents, clinical trial databases, and electronic health records, identifying hidden connections between genes, diseases, drugs, and adverse effects. These approaches facilitate hypothesis generation by revealing unexpected associations worthy of experimental investigation, support target identification by connecting disease mechanisms with druggable targets, and enable drug repurposing by identifying approved medications with potential efficacy for novel indications. Knowledge graphs integrating diverse data sources provide frameworks for computational reasoning about disease biology and therapeutic opportunities.

Molecular dynamics simulations model atomic-level movements and interactions of biological molecules over time, providing insights into protein conformational changes, ligand binding mechanisms, and allosteric regulation. These simulations inform structure-based drug design by revealing cryptic binding pockets, predicting binding free energies, and identifying optimal compound binding modes. Enhanced sampling methods overcome timescale limitations of conventional molecular dynamics, enabling simulation of slow conformational changes relevant to drug binding. For tissue repair targets, simulations might reveal allosteric sites enabling selective activation of growth factor receptors or identify stabilizing modifications for peptide therapeutics.

Quantum computing technologies, though still early in development, promise exponential acceleration of certain computational chemistry tasks. Quantum algorithms can theoretically simulate quantum mechanical systems including chemical reactions and molecular orbital structures with dramatically greater efficiency than classical computers. While practical quantum advantage for drug discovery awaits further hardware development and algorithm refinement, pilot studies demonstrate feasibility for specific applications including electronic structure calculations and reaction mechanism predictions.

Cryo-electron microscopy has revolutionized structural biology by enabling near-atomic resolution structure determination for proteins, protein complexes, and membrane proteins previously refractory to crystallographic approaches. This technology facilitates structure-based drug design for previously intractable targets and reveals dynamic conformational changes informing mechanism understanding. Single-particle cryo-electron microscopy can resolve multiple conformational states within heterogeneous samples, capturing functionally relevant structural dynamics. For tissue repair targets including growth factor-receptor complexes and extracellular matrix assemblies, cryo-electron microscopy provides structural insights enabling rational therapeutic design.

Challenges

Pharmaceutical development for acute surgical complications including iatrogenic esophageal perforation faces distinctive challenges beyond those encountered with chronic disease therapeutics. Low incidence of specific complications limits clinical trial feasibility, requiring multicenter collaboration or extended enrollment periods to achieve adequate sample sizes for definitive efficacy assessment. Severity and rapid progression of conditions like esophageal perforation create ethical tensions between research participation and immediate therapeutic intervention, potentially precluding randomization or blinded treatment allocation. Heterogeneity in injury mechanisms, severity, anatomic location, timing of diagnosis, and patient comorbidities introduces substantial outcome variability complicating efficacy demonstration.

Standard of care for surgical complications typically involves multifaceted interventions including surgical or endoscopic repair, antimicrobial therapy, nutritional support, and intensive care management, creating challenges in isolating additive benefits of novel pharmacological interventions. Surgical skill variability, institutional differences in management protocols, and evolution of techniques over study duration introduce confounding potentially obscuring treatment effects. Surrogate endpoints including biochemical markers or imaging findings may not reliably predict patient-centered outcomes like mortality, functional recovery, or quality of life, necessitating large long-term studies to assess clinically meaningful benefits.

Translational challenges arise from fundamental differences between experimental models and clinical disease. Animal models may not accurately recapitulate human tissue injury mechanisms, healing kinetics, immune responses, or microbiological factors. Controlled experimental injuries differ substantially from clinical scenarios involving variable contamination, delayed diagnosis, and patient comorbidities affecting healing capacity. Preclinical efficacy in healthy young animals may not predict responses in elderly patients with diabetes, malnutrition, immunosuppression, or other conditions impairing tissue repair. These translational gaps contribute to high clinical trial failure rates despite promising preclinical results.

Economic challenges include limited market size for rare acute complications potentially insufficient to justify substantial development investment by commercial pharmaceutical companies. Orphan drug designations and regulatory incentives aim to encourage development for rare conditions but may inadequately address acute surgical applications. Academic and non-profit drug development initiatives may partially fill gaps but face sustainability challenges and limited resources for comprehensive clinical development programs. Public-private partnerships and government funding mechanisms represent potential solutions but require careful design ensuring appropriate risk-sharing and benefit distribution.

Precision medicine approaches for tissue repair face challenges including identification and validation of predictive biomarkers, development of companion diagnostics, and demonstration that biomarker-guided therapy improves outcomes compared with empirical treatment.

Genetic and molecular heterogeneity in healing capacity, inflammatory responses, and infection susceptibility may require patient stratification, but identifying actionable biomarkers measurable rapidly enough to guide acute treatment decisions proves challenging. Developing and validating companion diagnostics adds complexity and cost to development programs while potentially limiting market size to biomarker-positive patient subsets.

Ethical and Regulatory Considerations

Ethical frameworks governing research in acute surgical complications must balance imperatives to generate evidence supporting improved therapies against obligations to protect vulnerable critically ill patients. Informed consent processes face substantial challenges when patients may be sedated, intubated, or otherwise unable to provide consent during acute illness. Exception from informed consent regulations permit emergency research under specified conditions including life-threatening situations where available treatments are unproven or unsatisfactory, therapeutic window precluding time for consent, and community consultation with public disclosure preceding enrollment. These provisions enable research in conditions like esophageal perforation but require rigorous safeguards protecting participant welfare.

Deferred consent or consent from legally authorized representatives enables enrollment during acute illness with subsequent patient consent when feasible, but raises concerns about autonomy and surrogate decision-making accuracy. Patients enrolled under emergency research exceptions or deferred consent must be informed as soon as possible and given opportunities to withdraw if desired. Community consultation processes engage stakeholders including potential participants, family members, clinicians, and community representatives in protocol review and approval before study initiation, ensuring community acceptance and addressing concerns about research conduct.

Data and safety monitoring boards provide independent oversight of clinical trials, reviewing accumulating safety and efficacy data at predetermined intervals and recommending study modifications including early termination for safety concerns, futility, or overwhelming efficacy. For studies in critically ill patients, enhanced monitoring with more frequent interim analyses and lower thresholds for stopping rules protects participant safety while enabling efficient identification of beneficial or harmful interventions. Stopping guidelines must balance statistical considerations with clinical and ethical factors including potential benefits and risks to enrolled participants versus future patients.

Regulatory frameworks aim to ensure therapeutic safety and efficacy while facilitating timely access to beneficial treatments. The Food and Drug Administration and European Medicines Agency employ rigorous review processes requiring substantial evidence from adequate and well-controlled trials demonstrating favorable benefit-risk profiles. For acute surgical complications, traditional regulatory paradigms developed primarily for chronic disease therapeutics may require adaptation addressing unique challenges including limited patient populations, difficulty conducting placebo-controlled trials, and importance of rapid treatment initiation.

Accelerated approval pathways enable earlier market authorization based on surrogate endpoints reasonably likely to predict clinical benefit, with post-approval confirmatory trials required. These mechanisms have substantially reduced approval timelines for therapies addressing serious conditions with unmet needs, though appropriate balance between access and evidence remains debated. Breakthrough therapy designation provides enhanced regulatory interaction and expedited review for drugs demonstrating substantial improvement over available therapies based on preliminary clinical evidence. For tissue repair agents demonstrating compelling early efficacy signals, these expedited pathways could facilitate clinical availability while additional confirmatory evidence accumulates.

Adaptive licensing approaches propose iterative authorization initially limited to specific patient populations or clinical contexts based on available evidence, with gradual expansion as additional data accumulate. This staged approach balances early access for patients lacking alternative options against uncertainty inherent in limited initial evidence. Real-world evidence generation through patient registries and post-marketing studies provides ongoing safety monitoring and effectiveness assessment informing benefit-risk evaluation. Implementation requires collaboration among regulators, manufacturers, payers, and healthcare systems ensuring appropriate utilization and systematic evidence collection.

Conclusion

Iatrogenic esophageal perforation represents a devastating complication with limited therapeutic options beyond surgical intervention and supportive care, exemplifying broader gaps in pharmaceutical development for acute surgical complications and critical care applications. The absence of targeted agents promoting tissue repair, modulating inflammation, or preventing infectious complications reflects systemic challenges in drug discovery including prolonged timelines, high attrition rates, and inadequate preclinical-to-clinical translation. Contemporary pharmaceutical development strategies including high-throughput screening, structure-based design, systems biology approaches, and translational research frameworks offer promise for accelerating therapeutic discovery and improving clinical success rates for these challenging applications.

Modern target identification leveraging genomic, transcriptomic, and proteomic technologies enables systematic identification of disease-relevant molecular pathways amenable to therapeutic intervention. Rigorous target validation employing genetic and chemical approaches combined with biomarker development builds confidence in therapeutic potential before substantial compound screening investment. High-throughput screening platforms evaluating millions of compounds against validated targets dramatically accelerate hit identification, while structure-based design and computational chemistry enable rational optimization toward clinical candidates with favorable pharmaceutical profiles.

Translational research emphasizing mechanistic disease understanding, predictive preclinical models, and pharmacometric approaches facilitates more efficient clinical development with improved probability of success. Innovative clinical trial designs including adaptive randomization, enrichment strategies, seamless phase II/III studies, and pragmatic embedded trials enhance feasibility and efficiency particularly for rare acute conditions. Artificial intelligence and machine learning technologies are revolutionizing multiple aspects of drug discovery from

virtual compound screening through clinical trial design, though careful validation and human oversight remain essential.

Application of these contemporary approaches to tissue repair and surgical complications could yield transformative therapeutics addressing critical unmet needs. Growth factors and their mimetics promoting epithelial proliferation and migration, anti-inflammatory agents modulating excessive immune responses impairing healing, antimicrobial peptides preventing infection in compromised tissues, and pro-angiogenic factors enhancing perfusion represent potential therapeutic avenues amenable to systematic development. Precision medicine approaches identifying patients most likely to benefit based on genetic wound healing capacity, inflammatory phenotypes, or microbiological profiles could optimize clinical trial designs and therapeutic utilization.

Challenges including low incidence limiting trial feasibility, ethical complexities in critically ill populations, translational gaps between animal models and clinical disease, and economic sustainability for rare acute indications require creative solutions. Collaborative networks enabling multicenter trials, regulatory flexibility accommodating innovative trial designs, academic-industry partnerships sharing development costs and risks, and public funding supporting research for conditions with limited commercial markets represent potential approaches. Patient and stakeholder engagement ensures research addresses clinically meaningful questions and incorporates perspectives of those affected by these devastating complications.

Future pharmaceutical development for acute surgical complications will require sustained innovation in discovery methodologies, translational frameworks, clinical trial designs, and regulatory approaches. Integration of emerging technologies including organoid disease models, human tissue engineering systems, artificial intelligence-driven compound discovery, and real-world evidence generation promises to accelerate development while improving clinical translation. Ethical imperatives to generate evidence supporting optimal care for patients with life-threatening complications demand continued investment in translational research infrastructure, methodological innovation, and collaborative frameworks enabling efficient, rigorous therapeutic development.

Figures



Fig 1: Overview of the drug discovery and development process from target identification to clinical implementation.



Fig 2: Description of high-throughput screening approaches and lead optimization processes in modern drug discovery.



Fig 3: Translational pathway illustrating progression from preclinical models to early- and late-phase clinical trials.



Fig 4: Conceptual integration of clinical complication management with translational and pharmaceutical development strategies.

Tables

Table 1: Comparison of conventional drug discovery approaches versus modern accelerated discovery strategies

Aspect	Conventional Drug Discovery	Modern Accelerated Discovery Strategies
Starting Point / Approach	Empirical screening of natural products and synthetic libraries	Target-centric: begins with comprehensive disease mechanism understanding and prospective target ID
Target Identification	Retrospective (after finding active compounds)	Prospective using genomics, transcriptomics, proteomics; systems biology & network-level opportunities
Compound Libraries & Screening	Small libraries (thousands to tens of thousands); low-throughput, sequential screening	Very large & diverse libraries; high-throughput screening of millions of compounds; automated, miniaturized assays
Screening Speed	Weeks to months per campaign	Campaigns completed within weeks
Lead Generation / Design	Sequential synthesis of analogs guided by intuition and experience	Structure-based drug design (X-ray, cryo-EM); fragment-based discovery; AI/virtual screening of billions
Computational Tools	Simple property calculations, 2D SAR correlations	Advanced computational chemistry, AI/ML for activity, selectivity, PK, toxicity, synthetic accessibility
Lead Optimization	Primarily medicinal chemistry intuition; sequential optimization	Multi-parameter optimization addressing potency, selectivity, ADME, safety; informed by modeling & structures
Preclinical Models	Limited animal models; poor translational predictivity	Disease models recapitulating human pathophysiology; mechanistic biomarkers; pharmacometric modeling
Safety Assessment	Empirical toxicology in animals; limited mechanistic investigation	Mechanistic toxicology; human-relevant *in vitro* systems (e.g. iPSC-derived tissues); off-target prediction
Clinical Development	Rigid sequential phases (I → II → III); no mid-study adaptation	Adaptive designs, seamless Phase II/III, biomarker enrichment, platform trials, real-world evidence
Typical Timeline	15–20 years from discovery to approval	10–12 years for many modern programs
Clinical Success Rate	<10%	Improved (through earlier de-risking and better candidate quality)
Cost per Approved	Billions of dollars; high late-stage attrition	Still high, but improved cost-efficiency due to reduced late-stage

Drug		failures
Main Source of Failure	Late discovery of inadequate efficacy or unacceptable toxicity	Earlier identification and mitigation of liabilities

Table 2: Advantages, limitations, and innovations across preclinical and clinical development phases

Phase	Advantages	Limitations	Key Recent Innovations
Preclinical – *In vitro* Systems	- Controlled conditions for mechanistic studies - High-throughput capability - Cost-effective vs. animal studies - No animal use (ethical benefit) - Human cell/tissue relevance	- No systemic context (metabolism, distribution, multi-organ effects) - Lack of complex tissue architecture & cell-cell interactions - Culture condition artifacts - Difficulty modeling chronic diseases	- 3D organoid cultures (architecture & heterogeneity) - Organ-on-chip microfluidic systems (perfusion, mechanical forces) - Bioprinted tissue constructs - Air-liquid interface cultures (barrier tissues)
Preclinical – Animal Models	- Intact organism physiology & systemic effects - Direct tissue drug concentrations & target engagement - Long-term/chronic toxicity & carcinogenicity assessment - Regulatory acceptance	- Species differences in metabolism, PK, target biology - Poor recapitulation of complex human diseases - Ethical concerns - High cost & time (especially large animals)	- Humanized models (human genes/tissues) - Conditional/inducible genetic systems - Advanced non-invasive imaging (longitudinal monitoring) - Improved rigor (randomization, blinding)
Phase I Clinical	- Controlled environment & intensive safety monitoring - Rapid execution (small N: 20–80) - Establishes human PK parameters - Initial PD/biomarker assessment	- Healthy volunteers may differ from patients - Small size misses rare AEs - No efficacy assessment - Challenges studying vulnerable populations	- Adaptive dose-escalation (Bayesian, PK-PD modeling) - Microdosing studies (subtherapeutic doses + sensitive analytics) - First-in-patient designs when appropriate
Phase II Clinical	- Early efficacy signals - Dose-response characterization - Biomarker evaluation & patient selection insight - Manageable size (100–300 patients)	- Imprecise effect estimates (limited power) - Selected populations → limited generalizability - Risk of false negatives & type I errors - High cost & go/no-go consequences	- Seamless Phase II/III designs - Response-adaptive randomization - Biomarker-based enrichment strategies - Platform / master protocol trials
Phase III Clinical	- Large N → precise efficacy estimates & high power - Diverse, multi-site enrollment → generalizability - Detection of less common AEs - Regulatory standard for approval	- Extremely high cost (hundreds of millions) - Long duration (3–5 years) - Rigid protocols may miss subgroup effects - Enrollment/retention challenges (especially rare diseases)	- Pragmatic designs (EHR-embedded) - Decentralized trials (telemedicine, home visits) - Adaptive designs (sample size re-estimation) - Event-driven analyses
Phase IV / Post-Marketing	- Very large populations → rare AE detection - Real-world effectiveness in diverse patients/practices - Long-term safety & effectiveness data - Hypothesis generation for new indications	- Observational → confounding & selection bias - Incomplete/poor-quality routine data - Delayed signal detection - Causality challenges	- Advanced causal inference (propensity scores, instrumental variables) - Disease/therapy registries - ML-based pharmacovigilance signal detection - Pragmatic randomized trials embedded in care systems

Table 3: Key translational challenges and therapeutic opportunities relevant to gastrointestinal injury and drug development

Category	Key Challenges / Opportunities	Description & Examples
Translational Challenges	Model & Patient Disparity	Differences between controlled animal models (typically healthy and young) and real-world clinical cases involving elderly patients with comorbidities such as diabetes and cardiovascular disease.
	Injury Context	Laboratory studies often use clean surgical incisions, whereas clinical perforations are traumatic, irregular, and frequently contaminated.
	Timing & Metrics	Immediate treatment in experimental models contrasts with delayed diagnosis in clinics; surrogate endpoints like mechanical strength may not accurately predict survival or long-term outcomes.
Epithelial Regeneration	Growth Factor Signaling	Application of EGFR, FGFR, and HGFR agonists, along with small molecules targeting negative regulators of epithelial repair pathways.
	Pathway Modulation	Activation of Wnt signaling to enhance stem cell proliferation and modulation of Notch signaling to restore epithelial barrier integrity.
	Advanced Delivery	Endoscopic delivery systems, bioabsorbable hydrogels, and targeting peptides enabling localized and sustained therapeutic release.
Anti-Inflammatory Strategies	Cytokine Control	Selective inhibition of TNF-α, IL-1β, and IL-6, along with inflammasome (NLRP3) blockers to limit excessive inflammatory damage.
	Resolution Promotion	Use of specialized pro-resolving mediators such as lipoxins and resolvins, and enhancement of regulatory T-cell responses to promote inflammation resolution.
Antimicrobial Approaches	Next-Generation Agents	Development of optimized antimicrobial peptides, antibiofilm compounds, and bacteriophage-based therapies.
	Host Modulation	Immunomodulatory antimicrobials that integrate pathogen elimination with enhancement of host immune defense mechanisms.
Perfusion & Fibrosis Control	Angiogenesis	Activation of VEGF and angiopoietin pathways, stabilization of HIF, and nitric oxide donors to improve vascularization and tissue oxygenation.
	Anti-fibrotic Strategies	Inhibition of TGF-β signaling and lysyl oxidase activity to prevent stricture formation and excessive collagen cross-linking.

Strategic Integration	Combination Therapy	Coordinated use of antimicrobials and pro-healing agents with temporal sequencing, such as initial anti-inflammatory therapy followed by regenerative stimulation.
	Precision Medicine	Application of multi-omics approaches (genomics, proteomics) and imaging biomarkers (PET, ultrasound) for patient stratification and personalized treatment.
Regulatory Pathways	Expedited Approval	Utilization of orphan drug designation, Breakthrough Therapy pathways, and real-world evidence to accelerate clinical translation and regulatory approval.

References

1. Brinster CJ, Singhal S, Lee L, Marshall MB, Kaiser LR, Kucharczuk JC. Evolving options in the management of esophageal perforation. Ann Thorac Surg. 2004;77(4):1475-1483.
2. Kaman L, Iqbal J, Kundil B, Kochhar R. Management of esophageal perforation in adults. Gastroenterol Res. 2010;3(6):235-244.
3. Søreide JA, Konradsson A, Sandvik OM, Øvrebø K, Viste A. Esophageal perforation: clinical patterns and outcomes from a patient cohort of Western Norway. Dig Surg. 2012;29(6):494-502.
4. Chirica M, Champault A, Dray X, Sulpice L, Munoz-Bongrand N, Sarfati E, *et al*. Esophageal perforations. J Visc Surg. 2010;147(3):e117-e128.
5. Biancari F, D'Andrea V, Paone R, Di Marco C, Savino G, Koivukangas V, *et al*. Current treatment and outcome of esophageal perforations in adults: systematic review and meta-analysis of 75 studies. World J Surg. 2013;37(5):1051-1059.
6. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of research and development costs. J Health Econ. 2016;47:20-33.
7. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.
8. Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov. 2013;12(8):569.
9. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, *et al*. How to improve research and development productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-214.
10. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical research and development efficiency. Nat Rev Drug Discov. 2012;11(3):191-200.
11. Guo JL, White PS, Bradfield JP. Genome-wide association studies in pharmacogenomics. Pharmacogenomics. 2011;12(7):1027-1037.
12. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, *et al*. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9(383):eaag1166.
13. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690.
14. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, *et al*. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10(3):188-195.
15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.
16. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds from screening libraries. J Med Chem. 2010;53(7):2719-2740.
17. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507-519.
18. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, *et al*. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475-486.
19. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, *et al*. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419-431.
20. Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: *in vitro* safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 2005;10(21):1421-1433.
21. Gussow AB, Park AE, Borges AL, Shmakov SA, Makarova KS, Wolf YI, *et al*. Machine-learning approach expands the repertoire of anti-CRISPR protein families. Nat Commun. 2020;11(1):3784.
22. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA Jr, *et al*. Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov. 2020;19(5):353-364.
23. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, *et al*. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477.
24. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-780.
25. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, *et al*. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013;499(7459):481-484.
26. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662-1666.
27. Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586-1597.
28. Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, *et al*. Long-term expanding human airway organoids for disease modeling. EMBO J. 2019;38(4):e100300.
29. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125.
30. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62-70.
31. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619-1620.
32. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454-463.
33. Bothwell LE, Greene JA, Podolsky SH, Jones DS.

Assessing the gold standard--lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175-2181.
34. Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674-678.
35. Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495-496.
36. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market 2009-2018. JAMA. 2020;323(9):844-853.
37. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov. 2004;3(5):417-429.
38. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, *et al*. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856-860.
39. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, *et al*. Use of genome-wide association studies for drug repositioning. Nat Biotechnol. 2012;30(4):317-320.
40. Pushkarna M, Sboner A, Elemento O, Cerione RA. Translational bioinformatics approach to combat cardiovascular disease and cancers. Prog Mol Biol Transl Sci. 2016;139:217-238.

How to Cite This Article
Sharma K, Sarveshwar. Iatrogenic esophageal perforation after ERCP: early recognition and outcome innovative strategies high-throughput screening and translational approaches for accelerated therapeutic development. Int J Med All Body Health Res. 2026;7(1):107-118. doi:10.54660/IJMBHR.2026.7.1.107-118.